JPMorgan analyst Anupam Rama raised the firm’s price target on Ultragenyx to $84 from $79 and keeps an Overweight rating on the shares. The analyst also added the shares to the firm’s Analyst Focus List. The company’s first half of 2024 is a catalyst rich period, and Ultragenyx appeared confident heading into key updates, the analyst tells investors in a research note. At current levels, the firm does not believe Ultragenyx shares appropriately reflect the probability adjusted potential of its “pipeline shots-on-goal.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RARE:
- Ultragenyx price target lowered to $124 from $131 at Stifel
- Mereo BioPharma provides update on pipeline progress, corporate developments
- Ultragenyx price target raised to $47 from $43 at Wedbush
- Ultragenyx reports preliminary 2023 revenue $430M-$435M, consensus $435.9M
- Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones